Summary of Key Points Development of malignant mesothelioma is usually associated with asbestos exposure. The most common genetic alterations in mesothelioma are deletion of CDKN2A/ARF , inactivation of NF2 , and mutation or deletion in BAP1. The eighth edition of…
Summary of Key Points Performance status is universally recognized as an independent prognostic factor and typically correlates with the extent of tumor burden. As first-line therapy, platinum agent plus etoposide or irinotecan remains the standard of care for the treatment…
Summary of Key Points Surgery remains the most effective curative approach for early-stage (IA–IIB) NSCLC. Selected cases with clinical stage IIIA disease equally benefit from radical resection. Stereotactic radiotherapy may be an alternative for selected medically inoperable patients. Long-term survival…
Summary of Key Points Immunotherapy has entered a new era in lung cancer and is rapidly changing the standard of care. Vaccines as monotherapies have shown marginal efficacy in certain settings. Program death-1 (PD1) and PD1 ligand (PDL1) inhibitors have…
Summary of Key Points Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, C-ros oncogene 1 (ROS1), ret proto-oncogene (RET) tyrosine kinase inhibitors (TKIs), several antiangiogenesis agents, and antiprogram death 1 (anti-PD1) immunotherapy are effective targeted treatments for lung…
Summary of Key Points Treatment of lung cancer is rapidly evolving. Large cell carcinomas as a group have therapeutically relevant driver mutations in nearly 40% of cases. Despite the recent failures of some agents, in 2015 the US Food and…
Summary of Key Points Discussed are tumor factors that affect treatment responses and outcome and host genetic elements that affect drug metabolism. Only pharmacogenomics elements that interact with chemotherapeutic agents are described. Prognostic biomarkers describe a specific tumor characteristic that…
Summary of Key Points Maintenance therapy offers the possibility of continued active treatment to delay disease progression and symptom deterioration and, more importantly, improved overall survival of patients with advanced nonsmall cell lung cancer (NSCLC) already treated with induction chemotherapy.…
Summary of Key Points There are a growing proportion of patients who are candidates for second-line therapy and beyond. Treatment choices are dictated by tumor histology, molecular phenotype (e.g., EGFR , ALK , ROS1 , etc.), and components of frontline…
Summary of Key Points The determination of tumor histology in nonsmall cell lung cancer (NSCLC) has become essential in treatment decision-making due to differential efficacy and toxicities seen with newer therapies. International Association for the Study of Lung Cancer (IASLC)…